ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Late-Breaking 2018"

  • Abstract Number: L03 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee

    Yusuf Yazici1, Timothy E. McAlindon2, Allan Gibofsky3, Nancy Lane4, Christian Lattermann5, Nebojsa Skrepnik6, Christopher Swearingen1, Anita DiFrancesco1, Jeymi Tambiah1 and Marc Hochberg7, 1Samumed, LLC, San Diego, CA, 2Division of Rheumatology, Tufts Medical Center, Boston, MA, 3Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY, 4Center for Musculoskeletal Health, University of California, Davis School of Medicine, Sacramento, CA, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 6Tucson Orthopaedic Institute, Tucson, AZ, 7University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: A previous Phase 2a study of SM04690, a small molecule, intra-articular (IA), Wnt pathway inhibitor, demonstrated positive effects on knee OA pain, physical function,…
  • Abstract Number: L04 • 2018 ACR/ARHP Annual Meeting

    Pediatric Open-Label Clinical Study of Rituximab for the Treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

    Paul Brogan1, Gavin Cleary2, Aimee O. Hersh3, Ozgur Kasapcopur4, Satyapal Rangaraj5, Rae S.M. Yeung6, Andrew Zeft7, Simone Melega8, Paul Brunetta9, Jennifer Cooper10, Pooneh Pordeli11 and Patricia B. Lehane12, 1Infection Inflammation and Rheumatology, UCL GOL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 2Alder Hey Children's Hospital, Liverpool, United Kingdom, 3Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, 4Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey, 5Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, 6Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 7Center for Pediatric Rheumatology & Immunology, The Cleveland Clinic Foundation, Cleveland, OH, 8F. Hoffmann-La Roche, Basel, Switzerland, 9Genentech, Inc., South San Francisco, CA, 10Pediatric Rheumatology, Univ. of California San Francisco, San Francisco, CA, 11Hoffmann-La Roche Ltd., Mississauga, ON, Canada, 12Roche Products Ltd., Welwyn Garden City, United Kingdom

    Background/Purpose: PePRS is a Phase IIa international, multicenter, open-label single arm study of rituximab in pediatric patients with newly diagnosed or relapsing GPA or MPA.…
  • Abstract Number: L05 • 2018 ACR/ARHP Annual Meeting

    Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study

    Maya H. Buch1, Bara Erhayiem2, Graham Fent2, Paul Baxter3, Elizabeth M.A. Hensor4, Adam McDiarmid2, Peter Swoboda5, Ananth Kidambi2, David Ripley2, Pankaj Garg2, Sarah Horton4, Raluca Bianca Dumitru4, Kamran Naraghi4, John Greenwood6, Paul Emery7, Sue Pavitt8 and Sven Plein2, 1Leeds Institute of Rheumatic & Musculosekeltal Medicine, University of Leeds & NIHR Biomedical Research Centre, Leeds, United Kingdom, 2Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, United Kingdom, 3Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, United Kingdom, 4Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Leeds Institute of Cardiovascular And Metabolic Medicine, University of Leeds, Leeds, United Kingdom, 6Leeds Institute of Cardiovascular And Metabolic Medicinee, University of Leeds, Leeds, United Kingdom, 7University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, 8Leeds School of Dentistry, University of Leeds, Leeds, United Kingdom

    Background/Purpose: We previously reported abnormal cardiac MRI (CMR)-determined aortic stiffness in patients with early, treatment-naive RA1,2. We now report on whether this vascular stiffness is…
  • Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting

    Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards

    Mark C. Genovese1, Kenneth C. Kalunian2, David Walker3, Jacques-Eric Gottenberg4, Kurt de Vlam5, Neelufar Mozaffarian6, Beatrix Bartok6, Franziska Matzkies6, Jie Gao6, Ying Guo6, Chantal Tasset7, John S. Sundy6 and Tsutomu Takeuchi8, 1Division of Immunology & Rheumatology, Stanford University, Stanford, CA, 2Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, 3Northumbria Healthcare, United Kingdom, United Kingdom, 4Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 5Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, 6Gilead Sciences, Inc., Foster City, CA, 7Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, 8Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…
  • Abstract Number: L07 • 2018 ACR/ARHP Annual Meeting

    VIB4920, a Novel, Engineered CD40L Antagonist Decreased Disease Activity and Improved Biomarkers of Immune Activation in Patients with Active Rheumatoid Arthritis in a Phase 1b, Multiple-Ascending Dose Proof-of-Concept Study

    Marius Albulescu1, Ulf Müller-Ladner2, Rachel Moate3, Kate Middleton3, Liangwei Wang4, Jorn Drappa4 and Gabor Illei5, 1Clinical Development, MedImmune, Cambridge, UK, Cambridge, United Kingdom, 2Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany, Bad Nauheim, Germany, 3MedImmune, Cambridge, UK, Cambridge, United Kingdom, 4Viela Bio, Gaithersburg, USA, Gaithersburg, MD, 5Viela Bio, Gaithersburg, USA, Gaithersberg, MD

    Background/Purpose: The CD40L/CD40 co-stimulatory pathway is important for T-cell-dependent antibody production and plays a central role in RA and other autoimmune diseases. VIB4920 (formerly  MEDI4920)…
  • Abstract Number: L08 • 2018 ACR/ARHP Annual Meeting

    High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response

    Anita Boyapati1, Jérôme Msihid2, Sergio Schwartzman3, Ernest Choy4, Mark C. Genovese5, Gerd R. Burmester6, Gordon Lam7, Toshio Kimura1, Jonathan Sadeh8 and Neil M.H. Graham1, 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 2Sanofi Chilly-Mazarin, Chilly-Mazarin, NJ, France, 3Hospital for Special Surgery, New York, NY, 4CREATE Center, Cardiff University School of Medicine, Cardiff, Great Britain, 5Division of Immunology & Rheumatology, Stanford University, Stanford, CA, 6Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, 7Atrium Health, Charlotte, NC, 8Sanofi, Bridgewater, NJ

    Background/Purpose: Clinical application of biomarkers to predict response to therapy is the next frontier in RA.  Despite the key role of IL-6 in RA, the…
  • Abstract Number: L09 • 2018 ACR/ARHP Annual Meeting

    Comparative Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors: A Cohort Study of Rheumatoid Arthritis Patients

    Rishi J. Desai1, Ajinkya Pawar2, Michael E Weinblatt3 and Seoyoung C. Kim4, 1Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4Rheumatology, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: A potentially increased risk of venous thromboembolism (VTE) was noted in pre-marketing trials of baricitinib, which is a Janus kinase inhibitor (JAK-I). This led…
  • Abstract Number: L10 • 2018 ACR/ARHP Annual Meeting

    Clinical Efficacy of Leflunomide/Hydroxychloroquine Combination Therapy in Patients with Primary Sjogren’s Syndrome: Results of a Placebo-Controlled Double-Blind Randomized Clinical Trial

    Timothy R.D.J. Radstake1, Eefje H.M. van der Heijden2, Frederique M. Moret3, Maarten R. Hillen4, Ana P. Lopes5, Toine Rosenberg6, Nard Janssen6, Aike A. Kruize7 and Joel A.G. van Roon3, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Rheumatology & Clinical Immunology/ Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 4Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 5Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 6Department of Oral-Maxillofacial Surgery, University Medical Center Utrecht, Utrecht, Netherlands, 7Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Primary Sjogren’s syndrome (pSS) is a systemic, progressive autoimmune disease characterized by secretory gland dysfunction which lacks effective therapy. Clinical trials in patients with…
  • Abstract Number: L15 • 2018 ACR/ARHP Annual Meeting

    The Diagnostic Accuracy of PET/CT Scan of the Head, Neck and Thorax Compared with Temporal Artery Biopsy in Patients Newly Suspected of Having GCA

    Anthony Sammel1, Edward Hsiao2, Geoffrey Schembri3, Katherine Nguyen4, Janice Brewer4, Leslie Schrieber5, Beatrice Janssen4, Peter Youssef6, Clare Fraser7, Elizabeth Bailey8, Dale Bailey8, Paul Roach8 and Rodger Laurent4, 1Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, 2Royal North Shore Hospital, St Leonards, Australia, 3Nuclear Medicine, Royal North Shore Hospital, St Leonards, Australia, 4Royal North Shore Hospital, St Leonards, Sydney, Australia, 5Northern Clinical School, University of Sydney, Sydney, Australia, 6Royal Prince Alfred Hospital, Camperdown, Sydney, Australia, 7Save Sight Institute, Sydney, Australia, 8Royal North Shore Hospital, Sydney, Australia

    Background/Purpose: The diagnostic accuracy of PET/CT against temporal artery biopsy (TAB) in patients suspected of having GCA has not been well studied. PET/CT has traditionally…
  • Abstract Number: L11 • 2018 ACR/ARHP Annual Meeting

    Etanercept and Methotrexate As Monotherapy or in Combination in Patients with Psoriatic Arthritis: A Phase 3, Double-Blind, Randomized Controlled Study

    Philip J. Mease1, Dafna D. Gladman2, David H. Collier3, Christopher T. Ritchlin4, Philip S. Helliwell5, Lyrica Liu6, Gregory J. Kricorian3 and James B. Chung3, 1Swedish Medical Center and University of Washington, Seattle, WA, 2University of Toronto, Toronto, ON, Canada, 3Amgen Inc., Thousand Oaks, CA, 4University of Rochester Medical Center, Rochester, NY, 5University of Leeds, Leeds, United Kingdom, 6Amgen Inc., South San Francisco, CA

    Background/Purpose:  Methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) such as etanercept (ETN) are often prescribed for psoriatic arthritis (PsA) either alone or in combination,…
  • Abstract Number: L16 • 2018 ACR/ARHP Annual Meeting

    Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness

    Dawn McGuire1, Neil Segal2, Samy Metyas3, Hans Richard Barthel4, Meghan Miller5, David Rosen5 and Yoshi Kumagai5, 1Orthotrophix, Incorporated, Oakland, CA, 2Physical Medicine and Rehabilitation, University of Kansas Medical Center, Kansas City, KS, 3Medvin Clinical Research, Covina, CA, 4Barthel Clinic, Santa Barbara, CA, 5OrthoTrophix, Incorporated, Oakland, CA

    Background/Purpose: TPX-100, a peptide derived from Matrix Extracellular Phosphoglycoprotein (MEPE), has been shown to induce articular cartilage regeneration after cartilage injury in animal models. A…
  • Abstract Number: L12 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Prior Inadequate Response or Intolerance to 1 or 2 Tumor Necrosis Factor Inhibitors

    Atul A. Deodhar1, Denis Poddubnyy2, Cesar Pacheco-Tena3, Carlo Salvarani4, Eric Lespessailles5, Proton Rahman6, Pentti Järvinen7, Juan Sanchez-Burson8, Karl Gaffney9, Eun Bong Lee10, Eswar Krishnan11, Silvia Santisteban11, Xiaoqi Li11, Fangyi Zhao11, Hilde Carlier11 and John D. Reveille12, 1Oregon Health & Science University, Portland, Portland, OR, 2Rheumatology, Campus Benjamin Franklin Charité – Universitätsmedizin, Germany and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, 3Facultad de Medicina, Universidad Autónoma de Chihuahua, Chihuahua, Mexico, 4Azienda USL-IRCCS di Reggio Emilia and Universita’ di Modena e Reggio Emilia, Reggio Emilia, Italy, 5Rheumatology, CHR Orléans and University of Orléans, Orléans, France, 6Medicine, Memorial University, St John's, NF, Canada, 7Rheumatology, Kiljava Medical Research, Hyvinkää, Finland, 8Hospital Infanta Luisa, Sevilla, Spain, 9Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust and Norwich Medical School, University of East Anglia, Norwich, United Kingdom, 10Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 11Eli Lilly and Company, Indianapolis, IN, 12Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX

    Background/Purpose: TNF inhibitors (TNFi) are recommended for patients with axial SpA (axSpA) who do not respond to or tolerate NSAIDs.  Some patients are inadequate responders…
  • Abstract Number: L17 • 2018 ACR/ARHP Annual Meeting

    Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study

    Christopher T. Ritchlin1, Arthur Kavanaugh2, Joseph F. Merola3, Georg Schett4, Jose U. Scher5, Richard B. Warren6, Deepak Assudani7, Thomas Kumke8, Barbara Ink7 and Iain B. McInnes9, 1University of Rochester Medical Centre, Rochester, NY, 2UC San Diego School of Medicine, La Jolla, CA, 3Brigham and Women's Hospital Harvard Medical School, Boston, MA, 4Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, 5Department of Medicine, NYU Langone Medical Center, New York, NY, 6The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, 7UCB Pharma, Slough, United Kingdom, 8UCB Pharma, Monheim am Rhein, Germany, 9University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: IL-17F shares structural homology and overlapping biologic function with IL-17A. In vitro studies demonstrate that IL-17F has biologic effector function that can modulate inflammation.…
  • Abstract Number: L13 • 2018 ACR/ARHP Annual Meeting

    Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial

    Xenofon Baraliakos1, Jürgen Braun2, Atul A. Deodhar3, Denis Poddubnyy4, Alan J. Kivitz5, Hasan Tahir6, Filip van Den Bosch7, Evie Maria Delicha8, Zsolt Talloczy9 and Anke Fierlinger9, 1Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, Herne, Germany, 2Rheumazentrum Ruhrgebiet Herne, and Ruhr University Bochum, Herne, Germany, Herne, Germany, 3Oregon Health & Science University, Portland, Portland, OR, 4Rheumatology, Campus Benjamin Franklin Charité – Universitätsmedizin, Germany and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, 5Altoona Arthritis & Osteoporosis Center, Duncansville, PA, 6Whipps Cross University Hospital, Barts Health NHS Trust, London, United Kingdom, 7Rheumatology, Universitair Ziekenhuis, Ghent, Belgium, Gent, Belgium, 8Novartis Pharma AG, Basel, Basel, Switzerland, 9Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States, East Hanover, NJ

    Background/Purpose: Clinical evaluation of efficacy and safety for long-term treatment for ankylosing spondylitis (AS) is important for treatment decision-making. Secukinumab (SEC), a fully human mAb…
  • Abstract Number: L18 • 2018 ACR/ARHP Annual Meeting

    A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab

    Gerd R. Burmester1, Frank Buttgereit1, Corrado Bernasconi2, Jose Maria Alvaro-Gracia3, Nidia Castro2, Maxime Dougados4, Cem Gabay5, Jacob van Laar6, J. Michael Nebesky2, Attila Pethö-Schramm2, Carlo Salvarani7, Marc Y. Donath8 and Markus R. John2, 1Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, 2F. Hoffmann-La Roche, Basel, Switzerland, 3Hospital Universitario de La Princesa IIS-IP, Madrid, Spain, 4Université Paris-Descartes, Paris, France, 5University Hospitals of Geneva, Geneva, Switzerland, 6University Medical Centre Utrecht, Utrecht, Netherlands, 7Università de Modena e Reggio Emilia, Modena, Italy, 8University Hospital Basel, Basel, Switzerland

    Background/Purpose: Guidelines recommend low-dose, short-duration glucocorticoid (GC) treatment for RA,1,2  but long-term use, especially at prednisone-equivalent doses >5 mg/d, should be avoided.2 Many patients (pts)…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology